Page 45 - 磁共振成像2024年7期电子刊
P. 45

特别关注｜｜Special Focus                  磁共振成像  2024年7月第15卷第7期  Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7


           进行诊断，为制订具有针对性的干预方案提供指导。                              [8]  于长春, 岳晓彤, 张小雷, 等 . PD-1/PD-L1 在肿瘤免疫治疗中的应用
                                                                   研究进展[J]. 吉林师范大学学报(自然科学版), 2022, 43(3): 112-118.
           此外有研究表明，PD-L1表达与其他参数（如年龄、性                              DOI: 10.16862/j.cnki.issn1674-3873.2022.03.015.
                                                                   YU  C  C,  YUE  X  T,  ZHANG  X  L,  et  al.  Research  progress  on  the
           别、分期和吸烟状况）之间没有显著相关性，PD-L1肿                              application  of  PD-1/PD-L1  in  tumor  immunotherapy[J].  J  Jilin  Norm
           瘤比例评分在鳞状细胞癌中显著较高，在腺癌中较                                  Univ Nat Sci Ed, 2022, 43(3): 112-118. DOI: 10.16862/j.cnki.issn1674-
                                                                   3873.2022.03.015.
             [35]
           低 。 本 研 究 却 发 现 患 者 的 年 龄 、FIGO 分 期 与                [9]  JOU J, KATO S, MIYASHITA H, et al. Cancer-immunity marker RNA
                                                                   expression  levels  across  gynecologic  cancers:  implications  for
           PD-L1 的表达有相关性。其原因可能是由于本研究                               immunotherapy[J].  Mol  Cancer Ther,  2023,  22(11):  1352-1362.  DOI:
                                                                   10.1158/1535-7163.MCT-23-0270.
           患者数较少，且均来源于同一单位，存在选择偏倚。                             [10] VRANIC  S,  GATALICA  Z.  PD-L1  testing  by  immunohistochemistry
           3.5 本研究的局限性                                             in  immuno-oncology[J].  Biomol  Biomed,  2023,  23(1):  15-25.  DOI:
                                                                   10.17305/bjbms.2022.7953.
                                                                                               18
               本文存在以下一些局限性：（1）本文选取的患者                          [11] KAIRA  K,  KUJI  I,  KAGAMU  H.  Value  of  F-FDG-PET  to  predict
                                                                   PD-L1 expression and outcomes of PD-1 inhibition therapy in human
           群体相对较少，存在抽样误差，有必要进行具有更大                                 cancers[J/OL]. Cancer Imaging, 2021, 21(1): 11 [2024-01-10]. https://
                                                                   pubmed.ncbi.nlm.nih.gov/33441183/. DOI: 10.1186/s40644-021-00381-y.
           样本量的多中心研究；（2）本研究属于回顾性研究，                            [12] KEEK  S  A,  LEIJENAAR  R  T,  JOCHEMS  A,  et  al.  A  review  on
           样本均于同一单位选取，无法避免选择偏倚，我们在                                 radiomics  and  the  future  of  theranostics  for  patient  selection  in
                                                                   precision  medicine[J/OL].  Br  J  Radiol,  2018,  91(1091):  20170926
           后续工作中将持续收集病例，扩大样本量，减小选择                                 [2024-01-10]. https://pubmed.ncbi.nlm.nih.gov/29947266/. DOI: 10.1259/
                                                                   bjr.20170926.
           偏倚；（3）ROI 的勾画区域与病理取材无法保证完全                          [13] MONACO L, BERNARDI E D, BONO F, et al. The "digital biopsy" in
           一致，结果可能存在选择偏倚；（4）单层病理切片不                                non-small  cell  lung  cancer  (NSCLC):  a  pilot  study  to  predict  the
                                                                   PD-L1  status  from  radiomics  features  of[18F]FDG  PET/CT[J].  Eur  J
           能完全反映肿瘤的空间异质性。                                          Nucl  Med  Mol  Imaging,  2022,  49(10):  3401-3411.  DOI:  10.1007/
                                                                   s00259-022-05783-z.
                                                               [14] WU  Z  J,  LIN  Q,  WANG  H  B,  et  al.  Intratumoral  and  peritumoral
                                                                   radiomics  based  on  preoperative  MRI  for  evaluation  of  programmed
           4 结论                                                    cell  death  ligand-1  expression  in  breast  cancer[J/OL].  J  Magn  Reson
                                   18
               综上所述，本研究表明 FDG PET/MR 影像组学                          Imaging,  2023  [2024-01-10].  https://pubmed.ncbi.nlm.nih.gov/37916918/.
                                                                   DOI: 10.1002/jmri.29109.
           特征与宫颈癌 PD-L1 表达差异有较强的相关性 ，                          [15] VISWANATHAN  C,  FARIA  S,  DEVINE  C,  et  al.  18F] -2-fluoro-
                                                                   2-deoxy-D-glucose-PET assessment of cervical cancer[J]. PET Clin, 2018,
           PET/MR 影像组学模型在预测 PD-L1 表达上具有更                           13(2): 165-177. DOI: 10.1016/j.cpet.2017.11.004.
           好的效能，能在临床上为宫颈癌患者评价 PD-L1 的                          [16] 李红岩, 夏晓天, 兰晓莉, 等 . PET 分子影像与肿瘤微环境的可视
                                                                   化 [J].  中 华 核 医 学 与 分 子 影 像 杂 志 ,  2019,  39(3):  174-177.  DOI:
           表达以优化个体诊疗方案，改善患者预后。                                     10.3760/cma.j.issn.2095-2848.2019.03.014.
                                                                   LI  H  Y,  XIA  X  T,  LAN  X  L,  et  al.  Visualization  of  tumor
               作者利益冲突声明：全体作者均声明无利益冲突。                              microenvironment  and  PET  molecular  imaging[J].  Chin  J  Nucl  Med
                                                                   Mol Imag, 2019, 39(3): 174-177. DOI: 10.3760/cma.j.issn.2095-2848.2019.
               作者贡献声明：孙洪赞设计本研究的方案，对稿                               03.014.
           件重要内容进行了修改，获得了沈阳市中青年科技                              [17] BOGDANOVIC  B,  SOLARI  E  L,  ASIARES  A  V,  et  al.  PET/MR
                                                                   technology:  advancement  and  challenges[J].  Semin  Nucl  Med,  2022,
           创新人才支持计划资助；李旺起草和撰写稿件，获                                  52(3): 340-355. DOI: 10.1053/j.semnuclmed.2021.11.014.
                                                               [18] VAN  GRIETHUYSEN  J  J  M,  FEDOROV  A,  PARMAR  C,  et  al.
           取、分析和解释本研究的数据；李朗俊、刘卓男获取、                                Computational radiomics system to decode the radiographic phenotype[J/OL].
                                                                   Cancer  Res,  2017,  77(21):  e104-e107  [2024-01-10].  https://pubmed. ncbi.
           分析或解释本研究的数据，对稿件重要内容进行了                                  nlm.nih.gov/29092951/. DOI: 10.1158/0008-5472.CAN-17-0339.
           修改；全体作者都同意发表最后的修改稿，同意对本                             [19] YEONG  J,  LUM  H  Y  J,  TEO  C  B,  et  al.  Choice  of  PD-L1
                                                                   immunohistochemistry  assay  influences  clinical  eligibility  for  gastric
           研究的所有方面负责，确保本研究的准确性和诚信。                                 cancer immunotherapy[J]. Gastric Cancer, 2022, 25(4): 741-750. DOI:
                                                                   10.1007/s10120-022-01301-0.
                                                               [20] 钟兰, 尹如铁 . 关于《宫颈癌免疫治疗现状与前景》的解读[J]. 华西药
                                                                   学杂志, 2022, 37(5): 594-600. DOI: 10.13375/j.cnki.wcjps.2022.05.026.
           参考文献[References]                                        ZHONG  L,  YIN  R  T.  Interpretation  of  "cervical  cancer
           [1]  BRAY  F,  FERLAY  J,  SOERJOMATARAM  I,  et  al.  Global  cancer   immunotherapy:  facts  and  hopes"[J].  West  China  J  Pharm  Sci,  2022,
              statistics  2018:  GLOBOCAN  estimates  of  incidence  and  mortality   37(5): 594-600. DOI: 10.13375/j.cnki.wcjps.2022.05.026.
              worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,   [21] BOSE  C  K.  Balstilimab  and  other  immunotherapy  for  recurrent  and
              68(6): 394-424. DOI: 10.3322/caac.21492.             metastatic  cervical  cancer[J/OL].  Med  Oncol,  2022,  39(4):  47
           [2]  TABATABAEI  F  S,  SAEEDIAN  A,  AZIMI  A,  et  al.  Evaluation  of   [2024-01-10]. https://pubmed.ncbi.nlm.nih.gov/35092506/. DOI: 10.1007/
              survival rate and associated factors in patients with cervical cancer: a   s12032-022-01646-7.
              retrospective  cohort  study[J/OL].  J  Res  Health  Sci,  2022,  22(2):   [22] 程凯, 石宇, 刘冬莲, 等 . PD-1/PD-L1 抑制剂在妇科肿瘤的研究进
              e00552 [2024-01-10]. https://pubmed.ncbi.nlm.nih.gov/36511264/. DOI:   展 [J].  肿 瘤 预 防 与 治 疗 ,  2020,  33(10):  903-908.  DOI:  10.3969/j.
              10.34172/jrhs.2022.87.                               issn.1674-0904.2020.10.014.
           [3]  WANG R Z, ZHANG Y, SHAN F P. PD-L1: can it be a biomarker for the   CHENG K, SHI Y, LIU D L, et al. Research progress of PD-1/PD-L1
              prognosis  or  a  promising  therapeutic  target  in  cervical  cancer?[J/OL].  Int   inhibitors in the treatment of gynecological cancers[J]. J Cancer Contr Treat,
              Immunopharmacol, 2022, 103: 108484 [2024-01-10]. https://pubmed.ncbi.  2020, 33(10): 903-908. DOI: 10.3969/j.issn.1674-0904.2020.10.014.
              nlm.nih.gov/34954558/. DOI: 10.1016/j.intimp.2021.108484.  [23] HASHIMOTO  K,  MURAKAMI  Y,  OMURA  K,  et  al.  Prediction  of
           [4]  ROTMAN J, DEN OTTER L A S, BLEEKER M C G, et al. PD-L1 and   tumor  PD-L1  expression  in  resectable  non-small  cell  lung  cancer  by
              PD-L2 expression in cervical cancer: regulation and biomarker potential  machine  learning  models  based  on  clinical  and  radiological  features:
              [J/OL].  Front  Immunol,  2020,  11:  596825  [2024-01-10].  https://pubmed.  performance  comparison  with  preoperative  biopsy[J/OL].  Clin  Lung
              ncbi.nlm.nih.gov/33424844/. DOI: 10.3389/fimmu.2020.596825.  Cancer,  2024,  25(1):  e26-e34  [2024-01-10].  https://pubmed. ncbi. nlm.
           [5]  AI  L  Y,  XU  A  T,  XU  J.  Roles  of  PD-1/PD-L1  pathway:  signaling,   nih.gov/37673781/. DOI: 10.1016/j.cllc.2023.08.010.
              cancer,  and  beyond[J]. Adv  Exp  Med  Biol,  2020,  1248:  33-59.  DOI:   [24] BEZZI C, ZAMBELLA E, GHEZZO S, et al. 18F-FDG PET/MRI in
              10.1007/978-981-15-3266-5_3.                         endometrial  cancer:  systematic  review  and  meta-analysis[J].  Clin
           [6]  HUI  E  F,  CHEUNG  J,  ZHU  J,  et  al.  T  cell  costimulatory  receptor   Transl Imag, 2022, 10(1): 45-58. DOI: 10.1007/s40336-021-00463-8.
              CD28  is  a  primary  target  for  PD-1-mediated  inhibition[J].  Science,   [25] 李影, 邱丽华. 宫颈癌MRI影像组学研究现状及进展[J]. 中国医学影像
              2017, 355(6332): 1428-1433. DOI: 10.1126/science.aaf1292.  技术, 2023, 39(9): 1407-1410. DOI: 10.13929/j.issn.1003-3289.2023.09.029.
           [7]  HUANG  W  J,  LIU  J  W,  XU  K,  et  al.  PD-1/PD-L1  inhibitors  for   LI  Y,  QIU  L  H.  Current  status  and  progresses  in  MRI  radiomics  of
              advanced or metastatic cervical cancer: from bench to bed[J/OL]. Front   cervical cancer[J]. Chin J Med Imag Technol, 2023, 39(9): 1407-1410.
              Oncol,  2022,  12:  849352  [2024-01-10].  https://pubmed.ncbi.nlm.nih.  DOI: 10.13929/j.issn.1003-3289.2023.09.029.
              gov/36313730/. DOI: 10.3389/fonc.2022.849352.                                       （下转第45页）

          ·38 ·                                                                       https://www.chinesemri.com
   40   41   42   43   44   45   46   47   48   49   50